Abstract
HIV-1, the causative agent of AIDS, is an obligate intracellular parasite that has both evolved to invade the complex human system and adapted to utilize the host machinery for its own propagation. A dynamic interaction between the virus and the host systems can be observed at every step of HIV-1 life cycle. Host factors are involved not only for mounting antiviral responses but are also hijacked by the virus to assist in its replication. The host factors are necessary for viral replication during entry, reverse transcription, nuclear import, integration, transcription, nuclear export, translation, assembly and budding. All retroviruses including HIV-1, are species-specific and the replication of the retroviruses is blocked in the restrictive host by the action of "host restriction factors". These restriction factors act as barriers to retroviral replication at various stages within the infected cell of a restrictive host. Nevertheless, HIV-1 virus has learned to subvert these antiviral responses and successfully propagate within the permissive host environment. This review article describes identification and mechanism of action of several pro- and anti-HIV-1 host factors. It is likely that we are just beginning to get a glimpse of an ongoing complex battle between the HIV-1 and the host, understanding of which should provide valuable information for the development of novel therapeutic strategies against HIV-1..
Keywords: HIV-1, innate immunity, host restriction factors, cellular proteins
Current HIV Research
Title: Dynamics of Virus-Host Interplay in HIV-1 Replication
Volume: 4 Issue: 2
Author(s): Masha Sorin and Ganjam V. Kalpana
Affiliation:
Keywords: HIV-1, innate immunity, host restriction factors, cellular proteins
Abstract: HIV-1, the causative agent of AIDS, is an obligate intracellular parasite that has both evolved to invade the complex human system and adapted to utilize the host machinery for its own propagation. A dynamic interaction between the virus and the host systems can be observed at every step of HIV-1 life cycle. Host factors are involved not only for mounting antiviral responses but are also hijacked by the virus to assist in its replication. The host factors are necessary for viral replication during entry, reverse transcription, nuclear import, integration, transcription, nuclear export, translation, assembly and budding. All retroviruses including HIV-1, are species-specific and the replication of the retroviruses is blocked in the restrictive host by the action of "host restriction factors". These restriction factors act as barriers to retroviral replication at various stages within the infected cell of a restrictive host. Nevertheless, HIV-1 virus has learned to subvert these antiviral responses and successfully propagate within the permissive host environment. This review article describes identification and mechanism of action of several pro- and anti-HIV-1 host factors. It is likely that we are just beginning to get a glimpse of an ongoing complex battle between the HIV-1 and the host, understanding of which should provide valuable information for the development of novel therapeutic strategies against HIV-1..
Export Options
About this article
Cite this article as:
Sorin Masha and Kalpana V. Ganjam, Dynamics of Virus-Host Interplay in HIV-1 Replication, Current HIV Research 2006; 4 (2) . https://dx.doi.org/10.2174/157016206776055048
DOI https://dx.doi.org/10.2174/157016206776055048 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanocarrier based Antiretroviral Drug Delivery Approaches
Pharmaceutical Nanotechnology Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study
Current HIV Research Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Developments of Combretastatin A-4 Derivatives as Anticancer Agents
Current Medicinal Chemistry The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Translating Pharmacogenetics and Pharmacogenomics: The Last 60 Years and the Rise of Collective Innovation as a Force Multiplier for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases
Current Gene Therapy Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Vulvar Leiomyomatosis: A Diagnostic Challenge Case Report
Current Women`s Health Reviews Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation
Current HIV Research Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets The Sojourn of Polymeric Micelles for Effective Brain Drug Delivery System
Current Drug Delivery IP6 in Cancer Therapy: Past, Present and Future
Current Cancer Therapy Reviews